Supplement to: Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 phase 3, randomized, double-blind, controlled trial

Supplementary appendix to the manuscript titled "Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 phase 3, randomized, double-blind, controlled trial" by Athanasios Tsianakas, Thierry Passeron, Nina Magnolo, Ulrike Blume-Peytavi, Virginie Kelly, Isaiah Day, Rocco Serrao, Emma Guttman-Yassky, Michael Sticherling, Adriána Evelin Csernus, Oscar M. Moreno-Arrones, Colleen Hamilton, James Cassella in the Journal of the American Academy of Dermatology.